Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine

Elisa Gremese; Antonio Carletto; Melissa Padovan; Fabiola Atzeni; Bernd Raffeiner; Anna Rita Giardina; Ennio Giulio Favalli; Gian Luca Erre; Roberto Gorla; Mauro Galeazzi; Rosario Foti; Fabrizio Cantini; Carlo Salvarani; Ignazio Olivieri; Giovanni Lapadula; Gianfranco Ferraccioli

doi:10.1002/acr.21768

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine

Elisa Gremese, Antonio Carletto, Melissa Padovan, Fabiola Atzeni, Bernd Raffeiner, Anna Rita Giardina, Ennio Giulio Favalli, Gian Luca Erre, Roberto Gorla, Mauro Galeazzi, Rosario Foti, Fabrizio Cantini, Carlo Salvarani, Ignazio Olivieri, Giovanni Lapadula, Gianfranco Ferraccioli

Risultato della ricerca: Contributo in rivista › Articolo in rivista

128 Citazioni (Scopus)

Abstract

Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti-tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs.

Lingua originale	English
pagine (da-a)	94-100
Numero di pagine	7
Rivista	ARTHRITIS CARE & RESEARCH
Volume	65
DOI	https://doi.org/10.1002/acr.21768
Stato di pubblicazione	Pubblicato - 2013

Keywords

Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Arthritis, Rheumatoid
Dose-Response Relationship, Drug
Female
Humans
Immunoglobulin G
Individualized Medicine
Longitudinal Studies
Male
Middle Aged
Obesity
Receptors, Tumor Necrosis Factor
Registries
Remission Induction
Treatment Outcome
Tumor Necrosis Factor-alpha

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1002/acr.21768

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Gremese, E., Carletto, A., Padovan, M., Atzeni, F., Raffeiner, B., Giardina, A. R., Favalli, E. G., Erre, G. L., Gorla, R., Galeazzi, M., Foti, R., Cantini, F., Salvarani, C., Olivieri, I., Lapadula, G., & Ferraccioli, G. (2013). Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. ARTHRITIS CARE & RESEARCH, 65, 94-100. https://doi.org/10.1002/acr.21768

@article{0851f8f7881d4c64af012abeb1e0bfd7,

title = "Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine",

abstract = "Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti-tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs.",

keywords = "Aged, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Rheumatoid, Dose-Response Relationship, Drug, Female, Humans, Immunoglobulin G, Individualized Medicine, Longitudinal Studies, Male, Middle Aged, Obesity, Receptors, Tumor Necrosis Factor, Registries, Remission Induction, Treatment Outcome, Tumor Necrosis Factor-alpha, Aged, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Rheumatoid, Dose-Response Relationship, Drug, Female, Humans, Immunoglobulin G, Individualized Medicine, Longitudinal Studies, Male, Middle Aged, Obesity, Receptors, Tumor Necrosis Factor, Registries, Remission Induction, Treatment Outcome, Tumor Necrosis Factor-alpha",

author = "Elisa Gremese and Antonio Carletto and Melissa Padovan and Fabiola Atzeni and Bernd Raffeiner and Giardina, {Anna Rita} and Favalli, {Ennio Giulio} and Erre, {Gian Luca} and Roberto Gorla and Mauro Galeazzi and Rosario Foti and Fabrizio Cantini and Carlo Salvarani and Ignazio Olivieri and Giovanni Lapadula and Gianfranco Ferraccioli",

year = "2013",

doi = "10.1002/acr.21768",

language = "English",

volume = "65",

pages = "94--100",

journal = "ARTHRITIS CARE & RESEARCH",

issn = "2151-464X",

publisher = "Hoboken, NJ : John Wiley & Sons",

}

Gremese, E, Carletto, A, Padovan, M, Atzeni, F, Raffeiner, B, Giardina, AR, Favalli, EG, Erre, GL, Gorla, R, Galeazzi, M, Foti, R, Cantini, F, Salvarani, C, Olivieri, I, Lapadula, G & Ferraccioli, G 2013, 'Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine', ARTHRITIS CARE & RESEARCH, vol. 65, pagg. 94-100. https://doi.org/10.1002/acr.21768

TY - JOUR

T1 - Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine

AU - Gremese, Elisa

AU - Carletto, Antonio

AU - Padovan, Melissa

AU - Atzeni, Fabiola

AU - Raffeiner, Bernd

AU - Giardina, Anna Rita

AU - Favalli, Ennio Giulio

AU - Erre, Gian Luca

AU - Gorla, Roberto

AU - Galeazzi, Mauro

AU - Foti, Rosario

AU - Cantini, Fabrizio

AU - Salvarani, Carlo

AU - Olivieri, Ignazio

AU - Lapadula, Giovanni

AU - Ferraccioli, Gianfranco

PY - 2013

Y1 - 2013

N2 - Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti-tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs.

AB - Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti-tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs.

KW - Aged

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Antirheumatic Agents

KW - Arthritis, Rheumatoid

KW - Dose-Response Relationship, Drug

KW - Female

KW - Humans

KW - Immunoglobulin G

KW - Individualized Medicine

KW - Longitudinal Studies

KW - Male

KW - Middle Aged

KW - Obesity

KW - Receptors, Tumor Necrosis Factor

KW - Registries

KW - Remission Induction

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

KW - Aged

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Antirheumatic Agents

KW - Arthritis, Rheumatoid

KW - Dose-Response Relationship, Drug

KW - Female

KW - Humans

KW - Immunoglobulin G

KW - Individualized Medicine

KW - Longitudinal Studies

KW - Male

KW - Middle Aged

KW - Obesity

KW - Receptors, Tumor Necrosis Factor

KW - Registries

KW - Remission Induction

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

UR - http://hdl.handle.net/10807/54003

U2 - 10.1002/acr.21768

DO - 10.1002/acr.21768

M3 - Article

SN - 2151-464X

VL - 65

SP - 94

EP - 100

JO - ARTHRITIS CARE & RESEARCH

JF - ARTHRITIS CARE & RESEARCH

ER -

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo